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Abstract:  A  successful  design  of  peptidomimetics  must  come  to  terms  with  χ-space 
control.  The  incorporation  of  χ-space  constrained  amino  acids  into  bioactive  peptides 
renders the χ
1 and χ
2 torsional angles of pharmacophore amino acids critical for activity 
and  selectivity  as  with  other  relevant  structural  features  of  the  template.  This  review 
describes histidine analogues characterized by replacement of native ʱ and/or β-hydrogen 
atoms with alkyl substituents as well as analogues with ʱ, β-didehydro unsaturation or  
C
ʱ-C
β cyclopropane insertion (ACC derivatives). Attention is also dedicated to the relevant 
field of β-aminoacid chemistry by describing the synthesis of β
2- and β
3-models (β-hHis). 
Structural modifications leading to cyclic imino derivatives such as spinacine, aza-histidine 
and analogues with shortening or elongation of the native side chain (nor-histidine and 
homo-histidine,  respectively)  are  also  described.  Examples  of  the  use  of  the  described 
analogues to replace native histidine in bioactive peptides are also given. 
Keywords: amino acids; alkyl substitution; conformation; histidine; stereoselective synthesis; 
χ-space 
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1. Introduction 
Design of peptidomimetics with a specific structure, conformation and topographical properties is a 
major issue in medicinal chemistry. Peptidic ligands elicit their bioactivity by the interaction of a portion 
of the three-dimensional (3D) structure with a complementary surface of the acceptor/receptor molecule 
or molecular complex. The peptide backbone acts as a scaffold which maintains the side chains involved 
in the interaction in the correct spatial position, providing at the same time the hydrogen bond network 
necessary  to  the  molecular  recognition  and  binding.  The  three-dimensional  shape  (topography)  and 
stereoelectronic properties of the side chain moieties involved in the binding process are critical for the 
interaction,  and  provide  the  necessary  complimentary  chemical/physical  environment  for  molecular 
recognition. During the past 30 years much effort has been expended to develop strategies for the design 
and synthesis of peptides with specific backbone conformation such as ʱ-helix, β-sheet, extended, γ- and 
β-turn structures. More recently, one of the major efforts has been shifted to the design and synthesis of 
novel amino acids with conformationally constrained side chains so as to improve the synthesis of highly 
selective and potent peptide hormone and neurotransmitter analogues. 
Peptide Dihedral Angles  
Natural  amino  acids  and  peptides  exist  with  a  native  conformational  bias  which  starts  at  the 
backbone level. Torsional (or dihedral) angles commonly used to define the spatial orientation of the 
backbone peptide bonds and side chains are defined as ˆ, ψ, ω, and χ as illustrated in Figure 1. 
Figure 1. Conformations of peptides: definitions of the ʦ, ψ, ω, χ
1 and χ
2 torsional angles. 
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The overall conformation of the peptide molecules is described by the sequence of the backbone 
torsion  angles.  The  first  torsion  angle  along  the  backbone  is  the  ʦ  angle.  This  is  defined  as  the 
torsional angle involving the bond sequence C(O)-N-C
ʱ-C(O) where both C(O) atoms are carbonyl 
carbons. The C
ʱ-C(O)-N-C
ʱ torsional angle is known as the  angle. Similarly is defined the ψ angle 
which involves the sequence N-C
ʱ-C(O)-N. Finally, the χ torsional angles of the side chain groups of Int. J. Mol. Sci. 2011, 12                       
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each  amino  acid  are  also  critical.  
1  is  defined  by  the  torsional  angle  N-C
ʱ-C
ß-C
γ  and  χ
2  by  the 
torsional angle C
ʱ-C
ß-C
γ-C
ʴ and so forth (Figure 1) depending on the structure and extension of the  
side chain. 
The range of the values which ʦ, ψ, ω and χ torsion angles can adopt along the backbone and inside 
each  side  chain  is  severely  restricted  by  steric  hindrance  thus  leading  to  sets  of  preferred  
torsional angles. 
The χ
1 torsional angles are well illustrated by referring to the Newman projection (Figure 2). There 
is an energy barrier between the discrete angles, with values of +60° , −60° , and 180°  having the most 
favorable energies. 
It is important to note that clockwise direction on the Newman projection is defined as a (+) while a 
counter clockwise direction projection is defined as a (−). 
Other angles in the Newman projection are less favorable due to a greater energy to overcome steric 
hindrance. X-ray crystallography of constrained peptides and calculations clearly show this [1,2].
 The 
torsional angles in the rotamers reported in Figure 2 are the different values of the χ
1 torsion angle. The 
ω angle is generally planar and trans configured with the C
ʱ atoms of the two involved residues. 
Notable exception is that of the X-Pro peptide bond which can be also found as cis with deviation from 
the planarity higher than that of the usual peptide junctions [3,4]. 
Figure 2. Newman projection of three staggered rotamers in L-amino acids. 
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Evaluation of the favored low energy conformations of the ʦ and ψ angles was first examined by 
Ramachandran and co-workers [5], about 30 years ago, and then by many other workers. These studies 
show that only certain regions of the ʦ, ψ space (often referred to as Ramachandran space) are actually 
accessible to L-amino acids. Interestingly these regions correspond to the classical secondary structures 
of peptides and proteins (ʱ-helix, β-sheet, extended, etc.). An equally critical area, though much less 
explored and relevant to the design of new structures, is that of the 3D shape of amino acid side chains. 
As illustrated in Figure 2, each χ
1 torsional angle (and some of the χ
2, χ
3, etc. subsequent torsional 
angles along the chains) can adopt three low energy staggered rotameric conformations: gauche(−), 
gauche(+),  and  trans.  The  corresponding  energy  conformation  is  not  expected  to  be  high  (about  
1–2 kcal/mole for most of the simple amino acid residues). 
Yet the orientation of the side chain of L-amino acid residues, with respect to the peptide or protein 
backbone,  will  be  dramatically  different  in  each  of  the  three  cases:  for  gauche(−)  χ
1:  orientation 
towards the N-terminus; for trans: orientation towards the C-terminus; for gauche(+): orientation over 
the backbone. In molecular recognition processes, the side chains will adopt generally one of these Int. J. Mol. Sci. 2011, 12                       
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three possible conformations, with preference for the gauche(−) > trans > gauche(+) for most natural 
L-amino acid residues. Clearly, the side chain conformations are critical to the molecular recognition 
and information transfer processes involving ligand-receptor/acceptor interactions [6,7]. 
2. Background  
The incorporation of χ-space constrained amino acids into bioactive peptides renders the χ
1 and χ
2 
torsional  angles  of  pharmacophore  amino  acids  critical  for  activity  and  selectivity  as  with  other 
relevant structural features of the template.  
A successful design of peptidomimetics in χ-space will depend upon several conditions: (1) side 
chains should adopt the preferred conformation found in natural amino acids; (2) the constraint should 
be compatible with backbone conformations; and (3) the constraint should be compatible with efficient 
binding  kinetics.  These  are  critical  issues  because  the  constrained  amino  acid  residues  must  not 
significantly interfere with the conformation of the constrained template, with binding of the ligand to 
its  receptor,  or  with  the  dynamic  processes  and  conformational  changes  that  accompany  
ligand-receptor interaction and information transduction [2]. 
During the design based on the topographical χ space control, authors concentrated their major 
efforts on aromatic amino acids. All peptide hormones and neurotransmitters have in fact one or more 
aromatic amino acid residues as key pharmacophore. Different structural features, chosen in order to 
constrain the χ space of aromatic amino acids, are shown in Figure 3. 
Histidine (His) is an important amino acid critically involved in receptor recognition and biological 
activity of many peptides and proteins [8]. 
The peculiar chemical properties of the imidazole ring are responsible for this. Histidine is often 
strategically located in a variety of biologically active peptides such as angiotensin [9], luteinizing 
hormone releasing hormone (LHRH) [10], liver cell growth factor [11], thyrotropin releasing hormone 
(TRH) and is preferential binding site for transition metal ions [12]. 
Despite the great attention dedicated to the structural modifications performed on phenylalanine, 
tyrosine and tryptophan aromatic residues and to the conformational and biochemical consequences of 
the incorporation of the obtained synthetic analogues into peptide backbones, the histidine residue has 
been only marginally treated. The presence of the basic and nucleophilic imidazole ring, which induces 
racemization  processes  and  requires  almost  invariably  specific  temporary  protection,  renders  the 
synthetic strategies more laborious than those encountered with any other aromatic amino acid. Here 
we  summarize  some  relevant  papers  performed  in  the  field  of  histidine  analogues  with  focus  on 
constrained models, characterized by the presence of ʱ- and/or β-substituents, capable of limiting the  
-space available to the imidazole side chain. Results concerning other relevant analogues, such as 
those pertaining to the relevant field of β-amino acids are also reviewed. 
 Int. J. Mol. Sci. 2011, 12                       
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Figure 3. General structure of some χ-constrained aromatic amino acids: (a) β and side 
chain  alkyl  substituted  amino  acids;  (b)  imino  acids;  (c)  ʱ-β  dehydro  and  ʱ-amino 
cyclopropanecarboxylic  acid  derivatives  (ACC);  (d)  β
2/β
3-homo-amino acids;  (e)  homo 
and nor-amino acids. 
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3. Nomenclature 
Histidine Derivatives 
Since the nomenclature of imidazole ring and histidine have been subjected to several changes in 
the years, data reported here adopt the following nomenclature: the nitrogen atoms of imidazole ring Int. J. Mol. Sci. 2011, 12                       
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are  denoted  by pros (π) and tele (˄) to  show their  position relative to  the side chain (near and  
far, respectively). 
The carbon atom between the two ring nitrogen atoms is numbered 2 (as in imidazole), and the 
carbon  atom  next  to  the  ˄  nitrogen  is  numbered  5.  The  carbon  atoms  of  the  aliphatic  chain  are 
designated ʱ and β [13] (Figure 4). 
Figure 4. Adopted notations for histidine and its analogues. 
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4. Chemistry 
4.1. α-Alkyl Substitution 
The strategy based on replacement of ʱ and β hydrogen atoms of histidine with alkyl groups started 
when  topographical  considerations,  relevant  to  the  stereochemical  features  required  for  receptor 
recognition and signal transduction, were still not well established. 
It has been demonstrated that ʱ substitution poorly affects in general the 
1 torsional angles. The 
more effective changes are found on the backbone and these analogues are in fact considered ʱ-helix 
and β-turn inducers [14].  
An  early  synthetic  method  (reported  by  Robinson  and  Shepherd  [15])  for  the  ʱ-substituted 
product 3 is the coupling reaction between methyl ʱ-nitropropionate and chloromethylimidazole 1 to 
give 2 followed by reduction of the nitro group (Scheme 1). 
Successively  (1974),  Suzuki  et  al.,  found  that  N-tosyl-acetoxy-methylimidazole  [16]
  4,  easily 
prepared from hydroxymethylimidazole [17], is a useful intermediate for the introduction of imidazole 
ring  in  the  amino  acid  skeleton.  Accordingly,  ʱ-methylhystidine  was  synthesized  by  reaction  of  
ʱ-isocyanoproprionate 5 with N-tosyl-acetoxymethylimidazole
 4, as shown in Scheme 2. Int. J. Mol. Sci. 2011, 12                       
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Scheme 1. Synthetic procedure for ʱ-methyl histidine [15]. 
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Scheme 2. Synthetic procedure for ʱ-methyl histidine [16]. 
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The coupling product 6 was obtained in 67% yield and was subsequently hydrolyzed with HCl to 
give ʱ-methylhistidine dihydrochloride 7 in 80% yield. 
Two years later DeGraw et al. used the route outlined in Scheme 3 to synthesize  ʱ-substituted 
histidines. 4-Chloromethylimidazole hydrochloride 8 [18],
 was added to a solution of an appropriate  
2-alkyl acetoacetate 9a–d,f or 2-acetylbutyrolactone 9e in ethanol solution containing sodium ethoxide 
to afford the 2-alkyl 2-(4-imidazolylmethyl)acetoacetate 10. When the keto ester 10 was allowed to 
react with a slight excess of hydrazoic acid in sulfuric acid solution, the N-acetylhistidine esters 11a–e 
were obtained in 50–70% yields. Under the acidic conditions employed, the ʱ-allyl-analogue 10f was 
apparently subjected to additional attack on the vinyl moiety, leading to an unidentified product rather 
than the anticipated product 11f. Schmidt
 [19] had qualitatively shown that in β-keto esters the HN3 
reagent afforded selective attack on the ketone carbonyl with subsequent rearrangement occurring at 
the ʱ-carbon. Synthesis of the histidines 12 and 13 were completed by acid hydrolysis of the amide and 
ester functions. This route seems to have been little used in the synthesis of ʱ-substituted amino acids, 
but especially valuable in the histidine series. 
An alternative synthesis (Scheme 4) of ʱ-substituted histidine was proposed by Kelley in 1977. The 
synthesis was modeled after the work of Robinson and Shepherd [15] and Sletzinger and Pfister [20], 
as outlined in Scheme 4.  
The appropriate ʱ-nitro ester 14 [21], (Scheme 4) was alkylated with 4-chloromethylimidazole [15], 
in  methanol  or  dimethylformamide.  In  the  case  of  the  ʱ-phenyl  analogue  14  (R1  =  CH2CH3;  
R2 = C6H5) hexamethylphosphoramide was required to obtain the product, even if the yield remained 
low. Reduction of the nitro esters 15 was best accomplished by catalytic hydrogenation to give the 
desired product 16. Although the reduction required a high catalyst to substrate ratio and extended 
reaction times, in all but one case the products were obtained in high yield and purity. Int. J. Mol. Sci. 2011, 12                       
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Scheme 3. Synthetic procedure for ʱ-alkyl histidine [18]. 
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In 1989, O’Donnell et al. [22] synthesized ʱ-methyl histidine by two complementary routes using a 
catalytic phase-transfer (PTC) alkylation procedure (Scheme 5). 
The first route involves benzylation of the Schiff base ester 17, prepared in 90% yield from alanine 
ethyl  ester  hydrochloride  and  p-chlorobenzaldehyde,  with  the  electrophile  18
  [23].
  In  the  second 
approach the appropriately protected histidine substrate 19 is ʱ-methylated by using the PTC method. 
The intermediate 19 is easily prepared in 83% yield in one pot procedure from histidine methyl ester 
dihydrochloride by condensation of the free amino ester (generated in-situ) with p-chlorobenzaldehyde 
followed by protection of the imidazole nitrogen with tosylchloride/triethylamine. Alkylation of 17 or 
19 was accomplished by catalytic solid-liquid phase transfer alkylation using powdered potassium Int. J. Mol. Sci. 2011, 12                       
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hydroxide in acetonitrile at 15–20 ° C with 10% Bu4NBr as the phase-transfer catalyst. The crude 
alkylated derivatives 20 (20a, R = Et, 47% crude; 20b, R = Me, 70% crude), obtained as oil, were 
hydrolyzed  directly  in  a  two-steps  sequence.  The  product  ʱ-methyl  histidine  was  obtained  as  its 
dihydrochloride 21 in overall yields of 27% and 41% from 17 and 19, respectively.  
Scheme 5. Synthetic procedure for ʱ-methyl histidine [22]. 
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4.2. β-Alkyl Substitutions 
A  synthetic  route  for  β-alkylhistidines  24  was  reported  by  Kelley  [24]  and  co-workers  as  a 
modification  of  Albertson’s  classic  synthesis  of  histidine  [25],  by  using  the  appropriate  
1-(4-imidazolyl)alkyl chloride 22 and the diethyl acetamidomalonate 23 (Scheme 6). 
Scheme 6. Synthetic procedure for β-alkyl histidine [24]. 
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The synthetic route afforded the desired amino acids as diastereoisomeric mixtures. No attempt was 
made to separate the diastereoisomers. 
A successful asymmetric synthesis of (2S,3S)-β-methylhistidine 31, by using 2-mesitylenesulfonyl 
(Mts-) as a protecting group at -N in the imidazole ring was reported by Hruby et al. [8] (Scheme 7). 
Scheme 7. Synthesis of (2S,3S)-β-methylhistidine [8]. 
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The synthesis started from the commercially available urocanic acid  25. This  was  treated with  
2-mesitylensulfonylchloride  MtsCl  in  sodium  hydroxide  solution  to  furnish  the  derivative  26  
-N protected at the imidazole ring. The protected urocanic acid was coupled by mixed anhydride 
method 27 to an optically pure chiral auxiliary according to a reported procedure [26] to give 28. The 
subsequent Michael addition and azide formation followed a highly enantioselective route (>99% as 
determined by 
1H NMR). Hydrolysis of the chiral auxiliary 29 to compound 30 led to the removal of 
the  Mts-protecting  group.  The  final  unprotected  β-methylhistidine  31  was  isolated,  purified  by  
ion-exchange column (Dowex 50X2-100) and recrystallized from water/ethanol [27]. According to the 
1H NMR spectra some epimerization was observed in the last two steps; thus the Mts- or another 
protecting group should be reintroduced for this use in peptide chemistry. Although the free imidazole 
group can apparently catalyze the epimerization process, the adoption of the Mts protection allowed 
the first successful asymmetric synthesis of a (2S,3S)-β-methylhistidine derivative. 
Recently,  Saha  et  al.  [28]  synthesized  β-amino  acids  based  libraries  on  solid  support,  
ancoring  4-formyl  imidazole  to  2%  cross-linked  PS-resin  using  the  convenient  2-Cl  trityl  linker.  
Horner-Emmons  condensation  was  conducted  on  resin  bound  aldehyde  with  an  excess  of  
tert-butylcarboxy  triethyl  phosphonoacetate  in  THF  32.  Lithium  amides  have  been  utilized  in 
conjugate  Aza-Michael  additions  to  ʱ,β-unsatured  systems  for  the  generation  of  protected  chiral  Int. J. Mol. Sci. 2011, 12                       
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β-amino acids 34 [29]. The amides were generated by pre-treating several amines with n-BuLi in THF 
at −78 ° C. The resulting lithium amides were added via cannula under N2 to a pre-swelled suspension 
of  resin  33  in  THF,  maintained  at  −78  ° C.  Then,  the  mixture  was  warmed  to  room  temperature 
followed by work up procedure. Cleavage after Aza-Michael addition, under mild-TFA conditions 
produced the tert-butyl ester products 35. Cleavage with 25–50% TFA-CH2Cl2 gave the deprotected  
β-amino acid products 36 (Scheme 8). 
Scheme 8. Aza-Michael reaction toward synthesis of β-amino acids on solid support [28]. 
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4.3. β,β–Dimethyl Substitution 
In 1976, De Graw et al. [30] prepared a series of substituted histidines and homo-histidines and 
evaluated the obtained compounds as inhibitors of specific histidine decarboxylase obtained from rat 
pyloric stomach. 
β,β-dimethyl  histidine  43  was  prepared  by  the  procedure  shown  in  Scheme  9;  
4-cyanomethylimidazole 37 was conveniently obtained in 70% yield from histidine by decarboxylation 
in sodium hypochloride solution [31]. 
Treatment of 37 with bis(trimethylsilyl)acetamide afforded an N-Me3Si intermediate which, when 
allowed to react with trityl chloride, gave the N-trityl-4-cyanomethylimidazole isomer 38 in 77% yield. 
Although shown as the 1-N-trityl derivative 39, the true position (N
 or N
) of tritylation was not 
established. The blocked nitrile 38 was converted to the anion by treatment with sodium hydride in 
hexamethylphosphoramide  (HMPA)  solution.  Subsequent  reaction  with  methyl  iodide  at  room 
temperature  afforded  a  mixture  of  methylation  products  containing  approximately  77%  of  the 
monomethylnitrile 39a. The dimethylnitrile 39b was obtained by exhaustive re-treatments to ensure 
complete  methylation.  Hydrolysis  of  the  nitriles  was  effected  by  sodium  hydroxide  in  hot  90%  
2-methoxy ethanol to afford the carboxylic acids 40a and 40b in 84% and 86% yields, respectively. 
Reduction  of  the  dimethyl  acid  40b  with  diisobutylaluminum  hydride  in  toluene  gave  a  mixture Int. J. Mol. Sci. 2011, 12                       
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containing  about  75%  of  the  aldehyde  41b  as  shown  by  NMR  analysis.  The  crude  product  was 
chromatographed to remove unreacted acid 40b and to effect a separation of the aldehyde from an 
undesired product regarded as the alcohol 44b. The crystalline aldehyde 41 was allowed to react with 
KCN/(NH4)2CO3 at 110 ° C in a bomb tube [32], to yield the hydantoin 42 as a crystalline product. 
Acid hydrolysis of 42 yielded the β,β-dimethyl histidine 43. 
Scheme 9. Synthesis of β,β-dimethyl histidine [30]. 
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4.4. Constrained “Imino Acids” 1,2,3,4-Tetrahydroquinoline Derivatives (Spinacines) 
The most important procedure to synthesize cyclic analogues of histidine uses the Pictet-Spengler 
reaction  [33,34]  or  modifications  thereof,  by  cyclocondensation  of  the  amino  acid  His  with 
formaldehyde in the presence of concentrated hydrochloride acid. In general these reactions proceed in 
good yield (70–97%) and enantiomerically pure amino acids can be obtained from enantiomerically 
pure precursors. If partial racemization [35]
 occurs fractional crystallization is necessary to obtain the 
desidered amino acid (yields: 90–99%) [36,37].
  
Among the variety of histidine analogs which provide a conformational restriction of the peptide 
backbone and/or of the lateral chain, the most extensively employed in structure-activity and metal-ion 
complexation studies have been the N
α-, N
- and N
-methyl histidine derivatives [38]. More recently, 
the (4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid) (Spinacine, Spi) has also been 
studied [39,40]. 
Reaction of L-His and formaldehyde to give Spi 47 was first reported by Wellisch in 1913 [41],
 but
 
only in 1991 Klutchko et al. [42] described the synthesis via Pictet-Spengler reaction on N
-substituted 
histidines,  of  a  large  number  of  Spi  derivatives  including  amide,  ester,  5-alkyl  and  acyl,  and 
regiospecific N
-akyl and aralkyl derivatives. 
L-Spi  has  been  also  synthesized  under  different  experimental  conditions  which  gave,  as  an 
intermediate, its N
-hydroxymethyl derivative Spi(-MeOH) [43] 46. In this case, the starting L-His in Int. J. Mol. Sci. 2011, 12                       
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0.1 M sodium phosphate buffer (pH 7.0) was reacted with a 30-fold molar excess of formaldehyde at 
room temperature for 4 days; the precipitate was collected by filtration, washed with cold water and 
dried. The product, separated from the reaction medium as crystal suitable for X-ray diffraction, was 
obtained in 93% yield (Scheme 10). The obtained Spi(-MeOH) 46 was dissolved in 1 M HCl and the 
solution concentrated at reduced pressure. The residue 45 was dissolved in water and the pH adjusted 
to 3.5. Absolute ethanol was added, obtaining crystals which were collected by filtration, washed with 
ethanol and dried (95% yield).  
Scheme 10. Synthesis of spinacine (Spi) and hydroxymethyl-spinacine Spi(-OMe) [43]. 
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An interesting use of the amino acid spinacine is reported by Guzman et al. [44] in their synthesis 
of cis/trans imidazopyridines spinacine derivatives (Scheme 11): 
Scheme 11. Synthesis of spinacine and derivatives [44]. 
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In particular, the 1-phenyl derivative 50 was synthesized by the method of Wille [45] through the 
base-catalyzed  Pictet-Spengler  reaction  of  histidine  48  with  benzaldehyde.  Aromatization  of  the 
tetrahydroimidazopyridine derivative 49 with selenium dioxide readily afforded 50 as free base. 
X-ray Studies on Spinacine Derivatives 
Two tautomeric forms can be predicted for the amino acid spinacine, depending on the position of 
the hydrogen on the nitrogen atoms of the imidazole ring. 
X-ray  studies  reported  by  Andreetti  et  al.  [46],  showed  that  the  crystals  correspond  
to  the  tautomer  having  the  N(3)  atom  protonated  as  shown  in  Figure  5,  in  which  the  bond  
distances  are  also  reported.  Thus,  the  compound  corresponds  to  the  amphionic  form  of  the  
4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic  acid.  Condensation  of  imidazole  with Int. J. Mol. Sci. 2011, 12                       
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tetrahydropyridine removes the  electron delocalisation on the imidazole and produces a double 
bond localized on C(2)-C(7) [C(2)-C(7) = 1.331(10) Å]. The other bond distances and angles are in 
agreement with the hybridisation state of the atoms. The imidazole ring and the C(6) and C(3) atoms 
lie on a plane whereas C(4) and N(1) are out of that plane by 0.208 and −0.568 Å respectively; this 
as a consequence of the sp
3 character of the four atoms of the six-membered ring. The torsional 
angles around the N(1)-C(3) and C(4)-C(6) are −25.6°  and 30.8°  respectively. The carboxyl group is 
equatorial and orientated in such a way that one oxygen points to the NH2
+ group to compensate the 
opposite electrical charge. 
Figure 5. An ORTEP view of Spi [46]. 
 
Solid state structure of spinacine analogues have been recently reported by Bertolasi et al. [43] 
(Figure 6) and one of these is that Spi(MeOH) 46 which crystallizes with a water molecule and its 
structure  displays,  like  that  of  Spi,  a  zwitterionic  character.  The  carboxylate  group  is  situated  in 
equatorial  position  and  is  rotated  by  about  10°   around  the  N1-C4  bond,  the  torsion  angles  
O1-C5-C4-N1  and  O2-C5-C4-N1  being  −10.2(2)°   and  170.3(2)° ,  respectively.  This  conformation, 
observed also in the structure of Spi and other amino acids [46], is favored by a short electrostatic 
interaction of 2.618(2) Å between the negative charged O2 atom and the positive N1. Bond distances and 
angles  are  within  the  normal  ranges;  in  particular,  comparing  the  present  structure  with  those  of 
imidazole [47], and L-His [48], it can be observed that the hydroxymethyl substituent at N3 and the 
condensation with tetrahydropyridine do not produce significant variations in the imidazole geometry. 
The tetrahydropyridine ring C2-C7-C6-C4-N1-C3 adopts a half-chair conformation 
5H4 with puckering 
parameters QT = 0.483(1) Å, ˆ = −145.6(3)°, θ = 48.0(2)° and ΔC2(C2–C7) = 0.0182(7) Å [49,50]. Int. J. Mol. Sci. 2011, 12                       
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Figure  6.  An  ORTEP  view  of  Spi(MeOH)
.H2O  showing  thermal  ellipsoid  at  30% 
probability [43]. 
 
4.5. 1-Amino-2-(4-imidazolyl)cyclopropanecarboxylic Acid Derivatives (ACC) 
The most general route to His derivatives containing a cyclopropane ring between the C
α and the C
β 
carbon  atoms  (ACC  derivatives)  involves  cyclopropanation  of  2-aryl-4-benzylideneoxazolones, 
formed by 1,3-dipolar  cycloaddition  of diazomethane followed by thermolysis of the intermediate 
pyrazoline.  The  cyclopropanation  reaction  works  moderately  well  and  the  subsequent  chemical 
transformations provide the amino acids in low to moderate overall yield (8–38%) [51].  
An  attractive  pathway  to  ACC  53  appears  the  addition  of  diazomethane  to  
4-[(1-acetyl-4-imidazolyl)methyl-ene]-2-phenyl-2-oxazolin-5-one 51 followed by hydrolytic cleavage 
of the oxazolone ring 52 [52] (Scheme 12). 
Scheme 12. Synthesis of ACC derivative [52]. 
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The  choice  of  this  route  follows  the  findings  of  Awad  et  al.  [53]  and  Mustafa  et  al.  [54],  
according  to  which  the  carbon-to-carbon  double  bonds,  exocyclic  to  certain  hetero  rings,  
including  oxazolones,  react  with  diazomethane  to  give  cyclopropane  derivatives.  Moreover,  
Awad et al. [53], have cleaved the azlactone 1,5-diphenyl-6-oxa-4-azaspiro-[2,4]hept-4-en-7-one to  
1-benzamido-2-phenylcyclopropanecarboxylic acid thus showing that the N-benzoyl group could be 
hydrolyzed under conditions which would not affect the cyclopropane ring. Int. J. Mol. Sci. 2011, 12                       
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4.6. α,β-Dehydro Amino Acids 
In 1990 Easton and co-workers reported a method for the diastereoselective conversion of amino 
acids to their β-hydroxy derivatives by direct side chain bromination of the amino acid derivatives with 
NBS, followed by treatment with silver nitrate in aqueous acetone [55–57]. 
The  side  chain  bromination  requires  an  N-protecting  group,  such  as  phthaloyl  or 
trifluoromethanesulfonyl, in order to deactivate the ʱ-position toward hydrogen atom abstraction [58]. 
Crich et al. [59] reported the use of N,N-di-tert-butoxycarbonyl protected amino acids in Easton’s 
protocol and the advantages that this strategy affords to the synthesis  of ʱ,β-dehydrohistidine and  
β-hydroxyhistidine (Scheme 13). 
The radical bromination of 54 [60] provided the threo bromide 55 and the trans oxazolidinone 56. 
This mixture was subsequently treated with silver nitrate in acetone to afford the trans oxazolidinones 
57  and  58,  which  differ  by  the  presence  of    t-butoxycarbonyl  group,  in  62%  yield.  Attempted 
hydrolysis  of  57  or  58  under  a  wide  variety  of  conditions  produced  the  ʱ,β-dehydrohistidine  
derivative 60. The free imidazole nitrogen is responsible for the elimination reaction thus, imidazole 
protecting group, stable under mild basic conditions, would solve the problem. Product 58 was also 
reacted with trityl chloride and triethylamine in dichloromethane and, after removal of the excess trityl 
chloride, the reaction mixture was treated with catalytic cesium carbonate in methanol leading directly 
to the formation of the desired (2S,3S) β-hydroxyhistidine derivative 59 in 74% yield (Scheme 13). 
Scheme 13. Synthesis of ʱ,β-dehydro-histidine [59]. 
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In 1980 Battersby et al. [61] realized a stereoselective synthesis of (ʱS, βS)-[β-
3H1]histidine and 
(ʱS, βR)-[β-
3H1]histidine, obtaining as intermediate, the 2-acetamido-3-[imidazol-4(5)yl-acrylic]acid 
(Scheme 14). In the first approach, NaBD4 or BT3 were added to a solution of 4(5)-formylimidazole to 
obtain compound 61a or 61b. These were then oxidized by MnO2 or BaMnO2 to the aldehyde 62a  
or  62b.  Condensation  of  the  aldehyde  with  N-acetylglycine  in  acetic  anhydride  afforded  the  
oxazolinone 64 and 65 which were converted into the required acrylic acid 67 and 68 by mild basic 
hydrolysis. In the second way, 4(5)-formylimidazole was directly condensed with N-acetylglycine to 
obtain compound 63. Then 63 was worked up as above to give the imidazolylacrylic acid 66.  
Scheme 14. Synthesis of ʱ,β-dehydro-histidine [61]. 
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Cativiela  et  al.  [62]  published  the  synthesis,  based  on  the  method  of  Battersby  [61],  of  
ʱ,β-dehydro-histidine with Z geometry around the double bond (Δ
Z-His). The synthesis starts from  
5-formylimidazole in Ac2O/AcONa which reacts with hippuric acid to give the intermediate azlactone; 
subsequent hydrolysis with sodium carbonate in water gave the desired Z configured compound.  Int. J. Mol. Sci. 2011, 12                       
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Recently,  an  example  of  azlactonization  of  ʱ,β-dehydro-histidine  (71)  starting  from  
5-hydroxymethyl-imidazole  (69)  was  reported  by  Parker  et  al.  [63];  as  illustrated  in  Scheme  15,  
(2S, 3S)-[3-
2H]histidinol, was synthesized by a stereochemically unambiguous route.  
Azlactone 70 was crystallized and its structure determined by X-ray crystallography. The ORTEP 
drawing of 70 (Figure 7) clearly indicates that the exocyclic double bond has the Z configuration, as 
shown in Scheme 15. 
Scheme 15. Synthesis of (Z)-ʱ,β-dehydro-histidine (
Z His) [63]. 
N
H
N
O H
N
H
N
H
O
N
H
N
OH D
N
H
N
CDO
N
N
N
O
O
Ph
D
Ac
N
N
NHBz
OH
O
D
Ac
NaBD4
Ac2O, NaOAc
hippuric acid
aq. Na2CO3
MnO2
MnO2
69
70
71  
X-ray crystal structure of azlactone 70 is illustrated in Figure 7.  
Figure 7. An ORTEP view of azlactone 70 [63]. 
 
A Japanese patent [64] reported the synthesis of a series of new imidazole derivatives (Scheme 16). Int. J. Mol. Sci. 2011, 12                       
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Scheme 16. Synthesis of ʱ,β-dehydro-histidine [64]. 
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The 5-formylimidazole 72 is treated with tert-butoxycarbonylamino-(dimethoxy-phosporyl)-acetic-acid 
methyl ester 73 in THF in the presence of 1,1,3,3-tetramethylguanidine (TMG) at 0 ° C. The product (74) 
of the condensation reaction is E/Z diastereoisomeric mixture. 
4.7. Homo-Histidine  
The  ten-steps  synthesis  of  L-homo-histidine  (Figure  8)  by  Bloemhoff  and  Kerling  [65]  using  
N-benzyloxycarbonyl-L-glutamic  acid  75  as  starting  material,  was  revisited  by  Altman  et  al.  [66] 
(Scheme 17). 
Figure 8. Series of L-homo-histidines. 
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The imidazole ring was built from the gamma-carboxyl group while the ʱ-function was protected. 
The  protecting  group  was  removed  in  the  last  step.  The  critical  step  in  this  procedure  involves 
imidazole ring closure with ammonia and formaldehyde forming copper salt. The reaction appears to 
be the most tedious step and does not exceed 50% yield. By submitting chloromethyl chetone 76 to 
cyclization conditions with formamidine acetate in ammonia the yield was greatly improved (71%), 
leading to the overall yield of 40%.  
This  method is not  applicable to  the preparation of a series of imidazole-containig amino acid 
derivatives by Silverman et al. [67] thus, a new enantioselective general procedure leading to 80a–e 
(Scheme 18) was devised by utilizing the reaction of various imidazolyl alkyl bromides 78b–e with 
chiral lithiated bislactim ether 79 as the key step. 
1-(N,N-dimethylsulfamoyl)imidazole  77  was  protected  with  a  tert-butyldimethylsilyl  group 
(TBDMS) by sequential treatment with n-butylithium followed by tert-butyldimethylsilyl chloride. The 
lithium salt of the 1,2-diprotected imidazole was allowed to react with a series of dibromoalkanes to 
afford bromoalkyl substituted imidazoles  78b–e. Carbon-carbon bond formation between the alkyl 
bromides and lithiated bislactim ether proceeded in good  yields. The homologated bislactim ether 
products 79a–e were hydrolyzed with 0.25 N HCl to the corresponding amino acid ethyl ester. Under Int. J. Mol. Sci. 2011, 12                       
 
 
2872 
these reaction conditions the TBDMS protecting group of the imidazole was cleaved. Removal of the 
sulfamoyl group requires relatively vigorous conditions (refluxing 30% HBr for 4 h), with consequent 
ethyl esters hydrolysis and formation of the desired amino acids 80b–e. The bromoethyl imidazole 
analogue 78a was not prepared by the route used for the other analogues, because the dibromoethane 
underwent elimination of HBr in the presence of n-butyllithium, and not a trace of the substitution 
product 79a was detected. 
A preparation of racemic homo-histidine from the readily available urocanic acid has been reported 
by Pirrung et al. [68] (Scheme 19).  
Urocanic acid was esterified and hydrogenated to give compound 81. As reported by Browne [69], 
the tritylation significantly improves its solubility in ethereal solvents, permitting DIBAL-H reduction 
in quantity to the aldehyde 82. Strecker reaction gives an aminonitrile whose hydrolysis, accompanied 
by the trityl group removal, produces homo-histidine 83 in 73% overall yield. 
A  patent  reported  the  synthesis  of  homo-histidine  [70],  useful  for  treating  renin  
associated hypertension. 
Scheme 17. Synthesis of L-homo-histidine [66]. 
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Scheme 18. Synthesis of L-homo-histidines [67]. 
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Scheme 19. Synthesis of racemic-homo-histidine starting from urocanic acid [68]. 
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4.8. Nor-Histidine  
The  accidental  discovery  of  sweet  dipeptide  derivative  L-aspartyl-L-phenylalanine  methyl  ester 
known as aspartame, was published several years ago [71]. Since then, a variety of analogues have 
been  prepared  by  different  research  groups  seeking  more  stable  and  more  potent  dipeptides.  The 
synthesis of imidazolylglycine [72] sweetener containing nor-histidine is given in Scheme 20: 
The protected N
α,N
-diBoc-imidazolylglycine derivative 84 was prepared by modification of a 
published procedure for the N
ʱ-Boc derivative [73,74]. Mixed anhydride coupling with (−)-ʱ-fenchol 
gave Boc-amino ester in low yield (25–30%). A major side product was the ethyl ester formed by the 
reaction  of  ethanol  released  from  the  mixed  anhydride  upon  reaction  with  fenchol.  This  severe 
limitation in the use of mixed anhydrides for ester formation is not a problem in amide formation 
where the nucleophilicity of the amine exceeds that of the ethanol released. Alternative coupling Int. J. Mol. Sci. 2011, 12                       
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procedures  also  gave  low  yields.  Acid  hydrolysis  gave  amine  85.  Coupling  with  
N-(tert-butoxycarbony1)-β-tert-butyl-L-aspartic  acid  p-nitrophenyl  ester  to  86  followed  by  acid 
hydrolysis gave sweetener 87. 
Scheme 20. Synthesis of imidazolylglycine sweetener containing nor-histidine [72]. 
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The importance of nor-histidine (Figure 9) as residue in biologically active compounds is shown in 
the study of Tagawa et al. [75]. 
Figure 9. Structure of nor-histidine and cephalosporine containing nor-histidine (Reference 75). 
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Recently, a panel of amino acid analogs and conformationally-restricted amino acids bearing a 
sulfonic acid were synthesized and tested for their ability to preferentially inhibit the obligate cysteine 
glutamate transporter system xc versus the vesicular glutamate transporter (VGLUT) [76]; The target 
conformationally-restricted amino acids were synthesized as shown in Schemes 21; imidazolylglycine 
was synthesized via hydrolysis of the corresponding hydantoin intermediate 88 [77–79]. Int. J. Mol. Sci. 2011, 12                       
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Scheme  21.  Synthesis  of  imidazolylglycine  via  the  corresponding  hydantoin  
intermediate [76]. 
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4.9. β
2-Homo-Histidine 
Due to the nucleophilic character of N-atom on the (1H-imidazolyl)methyl side chain of histidine, 
several undesired by-products can be formed during the synthesis of β-homo-histidines. Indeed, many 
routes have been tested, and most were not successful. (Scheme 22) [80]. 
Initial  attempts  of  diastereoselective  alkylation  (cf.  A  in  Scheme  22)  of  homo-glycine  derived 
acyloxazolidinones  III  (PG  =  Phth;  PG  =  Ph2C)  with  (1H-imidazol-4-yl)methyl  derivatives  II  
(PG’ = Trt, X = Cl; PG’ = Ts, X = MsO) were ineffective due to the low reactivity. In a second 
approach (cf. B in Scheme 22), the aldol addition of the oxazolidinone derivatives III with aldehydes 
IV (PG’ = Tr; PG’ = Ts), followed by deoxygenation under Barton-McCombie conditions, resulted in 
the isolation of degradation products caused by retro-aldol reactions, occurring during the oxygenation 
step.  Thus,  the  amidomethylation  reaction  via  Ti-enolates  was  attempted  (cf.  C  in  Scheme  22): 
treatment  of  the  acyloxazolidinone  V  (PG’  =  Tr)  with  the  electrophile  VI  resulted  in  a  complex 
mixture of inseparable products; although the desired compounds had been formed, long reaction times 
were  required  for  good  conversion,  causing  the  partial  cleavage  of  the  trityl  protecting  group.  
Seebach et al. envisaged the use of a more reactive electrophile, for instance, 1,3,5-trioxane (cf. D in 
Scheme 22), with subsequent OH/NH2 replacement. This route led eventually to the synthesis of the 
desired  β
2-homo-histidine  derivatives  for  solid  phase  syntheses.  For  the  preparation  of  the 
acyloxazolidinone  92,  1H-imidazole-4-acrylic  acid  (urocanic  acid)  was  selected  as  the  starting 
material. Hydrogenation of the urocanic acid, followed by esterification under acid conditions, gave 
the methyl ester 89, which was trityl protected to give crude 90. Product 90 was saponified to afford 
the acid 91 in 73% yield over four steps (Scheme 23). 
N-acylation  of  the  lithiated  chiral  auxiliary  4-isopropyl-5,5-diphenyl-1,3-oxazolidin-2-one  
(R)-DIOZ was accomplished by nucleophilic addition of the lithiated auxiliary (using BuLi in THF at 
0 ° C) to the pivaloyl mixed anhydride of 91 to give the acyloxazolidinone (R)-92, in 60% yield. The 
following aldol reaction was effected by reaction of the Ti-enolate of 92 with 1,3,5-trioxane to afford 
the hydroxymethyl derivative 93 in 70% yield. (Scheme 24). 
The next step required the replacement of the OH group of 93 by a N-substituent by means of a 
Mitsunobu reaction. Thus, treatment of (R,S)-93 with Ph3P, DIAD and either DPPA or hydrazoic acid 
afforded  the  azide  derivative  (R,S)-94  in  moderate  to  good  yields  (55  and  89%  resp.).  However 
attempts to cleave the auxiliary were not successful. Indeed, removal of the oxazolidinone group by 
BnOH/BuLi  afforded  the  elimination  product  95  (Scheme  24).  To  circumvent  this  problem,  the Int. J. Mol. Sci. 2011, 12                       
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hydroxymethyl derivative 93 was first treated with BnOH/BuLi to form the corresponding benzyl ester 
(S)-96, which was subsequently transformed to the azide (S)-97 under the Mitsunobu conditions in 
good yield (Scheme 25). 
Scheme 22. Retrosynthetic analysis for the preparation of the Fmoc-β
2hHis(Tr)-OH via 
alkylation, Mannich-Type reaction and aldol addition of chiral acyloxazolidinones [80].  
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Scheme 23. Preparation of the acyloxazolidinone (R)-92 starting from urocanic acid [80]. 
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Scheme  24.  Diastereoselective  aldol  reaction  of  (R)-92  with  1,3,5-trioxane.  Further 
transformation towards the formation of β
2-homo-histidine derivatives led to the formation 
of compound 95 [80]. 
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Scheme 25. Removal of the auxiliary with BnOLi followed by Mitsunobu Reaction and 
functional group modifications for the preparation of Fmoc-(S)-β
2hHis(Tr)-OH 98 [80]. 
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Simultaneous benzyl ester cleavage and azide reduction, by catalytic hydrogenation followed by 
Fmoc-protection, afforded the histidine derivative (S)-98 in moderate yield. It should be noted that the 
Tr protection group is stable under the hydrogenation conditions only to a certain extent; prolonged 
reaction times cause complete cleavage of that group. 
In this way, the synthesis of (S)-Fmoc-β
2hHis(Tr)-OH was achieved with an overall yield of 11% 
over ten steps from 4-isopropyl-5,5-diphenyl-1,3-oxazolidin-2-one (DIOZ). 
4.10. β
3-Homo-Histidine 
First  attempts  at  synthesizing  the  homo-histidine  derivatives  by  Seeback  et  al.  [80]  using  the  
Arndt-Eistert  homologation  from  Fmoc-His(˄-BOM)-OH,  Fmoc-His(˄-Tr)-OH,  Boc-His(˄-Bn)-OH, 
Boc-His(π-Bn)-OH, and Boc-His(˄-BOM)-OH were unsuccessful. Only Ts-protected histidines reacted 
with  CH2N2  to  form  the  corresponding  diazo  ketones,  probably  due  to  the  strong  
electron-withdrawing effect of the tosylate, which renders the 1H-imidazolyl-N-atom less nucleophilic. 
Thus, commercially available Fmoc-His(Ts)-OH and Boc-His(Ts)-OH were converted via their mixed 
anhydrides (NMM/ClCO2Et or NEt3/ClCO2
iBu) to the diazo ketones 99a  and 99b in 56 and 86% 
yields  respectively  (Scheme  26).  Attempts  at  converting  diazo  ketone  99a  to  a  β
3-homo-histidine 
derivative were shown to be ineffective, due to its insolubility in most solvents suitable for the Wolff 
rearrangement (e.g., BnOH, H2O, THF, dioxane, etc.). On the other hand, decomposition of diazo 
ketone 99b in the presence of the corresponding alcohol (MeOH, BnOH), by reaction with catalytic 
amounts  of  Ag
+  (CF3CO2Ag  dissolved  in  Et3N)  gave  the  Boc-protected  methyl  or  benzyl  
ester 100 as a mixture of three products in a 1:1:1 ratio. It was found that the Ag
+ ion interacts with the  
1H-imidazole ring inducing the partial displacement of the Ts protecting group from the ˄-N to the π-N, Int. J. Mol. Sci. 2011, 12                       
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as well as the complete removal of this protecting group. With this result at hand, they decided to  
use  Boc-His(πTs)-OH  as  starting  material  for  conversion  to  the  β
3-amino  acid  derivative  
Fmoc-β
3hHis(πTr)-OH.  Since the use of histidine derivatives  with  unprotected 1H-imidazolyl  side 
chains  for  peptide  couplings  in  solution  or  on  solid  support  are  known  to  cause  side  reactions,  
Tr-protected 1H-imidazolyl group of the ester 100 was used: treatment with TrCl and Et3N afforded 
compound 101 in quantitative yield. Hydrolysis of the methyl ester with LiOH in MeOH/H2O gave the 
acid  102  as  a  single  product  (Scheme  26).  The  Boc-β
3hHis(Tr)-OH  102  was  thus  prepared  from  
ʱ-Boc-His(Ts)-OH in ca. 75% yield over four steps. 
Scheme  26.  Preparation  of  the  β
3-homo-histidine  derivative  102  by  Arndt-Eistert 
homologation  of  Boc-His(Ts)-OH,  followed  by  Tr-protection  and  saponification  of  the 
methyl ester group in 101 [80]. 
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The successful preparation of Fmoc-β
3hHis(Tr)-OH was accomplished by using the Boc-protected 
homo-histidine esters 100 as starting materials. As such, Boc deprotection, followed by saponification 
or hydrogenolysis of the ester groups, gave the completely unprotected β
3-homo-histidine, which was 
then  phthaloyl(Phth)-protected  and  acidified  to  yield  the  HCl  salt  103  in  67%  yield.  Subsequent 
tritylation and N-Phth/N-Fmoc protecting-group exchange afforded the acid 104 in 61% yield over the 
three steps (Scheme 27). Int. J. Mol. Sci. 2011, 12                       
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Scheme 27. Preparation of Fmoc-β
3hHis(Tr)-OH 104 starting from 100 [80]. 
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In this way, the synthesis of Fmoc-β
3hHis(Tr)-OH was achieved in eight steps with an overall yield 
of 32%, starting from commercial Boc-His(Ts)-OH. 
Recently, Wyatt and co-workers [81] accomplished the synthesis of Boc-β
3hHis-(Boc)-OH 110 via 
the Kolbe reaction, i.e., (Scheme 28), by reducing  ʱ-Mts-His(Mts)-OMe 105 to the corresponding 
amino alcohol 106 in 58% yield, the OH group of which was then activated as its methanesulfonate 
107 (81%) and replaced by CN, to give compound 109; treatment of the methanesulfonate 107 with 
NaCN  (1  equiv.)  in  DMF  at  room  temperature  gave  mainly  the  aziridine  108,  which  could  be  
ring-opened by excess cyanide to give the desired nitrile 109; by using two or more equivalents of 
NaCN in DMF at room temperature the methanesulfonate 107 could be converted into the nitrile 109 
(63%)  in  a  single  step.  The  CN  group  was,  in  turn,  hydrolyzed  to  the  MeNH  group,  which  was  
Boc-protected to give the final product 110 in 7% yield over five steps. The authors state that this 
derivative is suitable for direct use in the synthesis of peptides, but so far no applications are known. Int. J. Mol. Sci. 2011, 12                       
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Scheme 28. Preparation of Boc-β
3hHis(Boc)-OH 110 via Kolbe reaction [81]. 
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4.11. Aza-Histidine  
The preparation of  aza-histidine (Figure  10) has  been already described  [82] and the synthetic 
routes published to date to obtain the fully deprotected amino acid are usually rather long (seven 
steps) [83]. 
Figure 10. Triazole analogue of histidine. 
N H2
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N N
O  
The recent development of the copper catalysed version of Huisgen cycloaddition allows the rapid 
access to 1,2,3-triazoles then aza-histidine derivatives have been obtained with this method, but no real 
attention has been paid to the removal of the protecting groups.  
Cintrat  et  al.  [82]  described  the  click  chemistry  based  access  to  fully  protected  aza-histidine, 
suitable for solid phase peptide synthesis (Scheme 29). 
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Scheme 29. Aza-histidine analogues via [3 + 2] Huisgen cycloaddition [82].  
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Aza-histidine were obtained using either copper-catalysed click chemistry or the more recently 
described ruthenium catalyzed cycloaddition, affording the 1,5-disubstituted triazole. Nevertheless, the 
latter requires the fully protected propargylglycine as starting material, since the catalyst does not 
allow the use of free carboxylic acids. Using either condition, rapid access to protected aza-histidine 
was demonstrated and the expected regioisomers were obtained with fair to satisfactory yields.  
Robinson  et  al. [84]  proposed  the  synthesis  of  DL-ʱ-Amino-l,2,3-triazole-4-propionic  acid  112, 
prepared by two independent routes. The catalytic hydrogenation of the oximino acid was extremely 
slow and the yield of the amino acid was small (17%). As an unambiguous method, the synthesis was 
also  accomplished  through  the  azlactone.  From  1,2,3-triazole-4-carboxaldehyde  111,  the  crude 
azlactone was obtained (52%) as a mixture of a ring-acetylated azlactone and a small amount of the 
non-acetylated form which was separated through its insolubility in chloroform. The latter compound 
was  readily  converted  into  the  former  by  acetylation.  Purified  samples  of  both  forms  gave  
ʱ-benzamido-1,2,3-triazole-4-acrylic acid dihydrate on hydrolysis (86–88%). The yield of the acrylic 
acid dihydrate from the crude mixture of azlactones was 85%. ʱ-Benzamido-l,2,3-triazole-4-propionic 
acid  was  obtained in  61%  yield  by hydrogenation  of the  acrylic acid  in  glacial acetic acid  using 
platinum oxide. Hydrolysis of this benzamido acid gave analytically pure DL-amino-l,2,3-triazole-4-
propionic acid 112 in 51% yield (Scheme 30). 
Scheme 30. Synthesis of DL-ʱ-Amino-1,2,3-triazole-4-propionic acid [84]. 
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Finally, Boyd et al. [85] explored variations in the imidazole portion of ʱ-adrenoceptor agonists, 
synthesizing a series of compounds, among them substituted (+,−)-aza-histidine, shown in Scheme 31. 
The  anion  of  ketoamide  113  was  alkylated  with  a  benzyl-protected  heteroarylmethyl  chloride  to 
furnish  the  protected  amidoketone  114.  Debenzylation  of  these  compounds  was  accomplished  by 
catalytic  hydrogenation  with  Pearlman’s  catalyst  [Pd(OH)2].  Finally,  the  target  compounds  were 
obtained by cyclization of these intermediate to thiazole. 
Scheme 31. Synthesis of substituted aza-histidine [85]. 
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5. Conclusions  
Topographical  considerations  are  an  important  approach  for  exploring  the  stereochemical 
requirements for receptor recognition and for signal transduction [2,86].  
In  this  approach,  side  chain  constrained  novel  amino  acids  are  designed  and  incorporated  into 
peptide templates. The use of pure chiral ʱ- or β-substituted amino acids in bioactive peptide ligands as 
key  pharmacophore  residues  has  proven  to  be  a  powerful  tool  for  understanding  ligand-receptors 
binding interaction and in peptidomimetics design [7]. 
One of the major goals of medicinal chemistry has been the design and synthesis of novel amino acids 
with conformationally constrained side chains in order to obtain highly selective and potent peptide 
hormone  and  neurotransmitter  analogues.  Incorporation  of  different  β-substituted  amino  acids 
(Figure 11), e.g., β-methylphenylalanine 115, β-methyltyrosine 116, β-methyl-2’,6’-dimethyltyrosine 
117,  and  β-methyltryptophan  118,  provided  new  insights  into  the  stereochemical  requirements  of 
peptide-receptor interactions [87–90]. Beta-methylhistidine (119 in Figure 11) is an important amino 
acid involved in signal transduction mechanism necessary to express biological activities [91] and in 
several key role receptor interactions, one of which being glucagone with its receptor.  
Topographical changes can greatly affect the potency and selectivity of peptidic ligands. Though 
this  approach  to  ligand  design  is  embryonal,  significant  progress  has  been  made  and  some  very 
impressive peptide-based ligands have been discovered. 
The  major  difficulties  to  synthesize  substituted  asymmetric  histidine  derivatives  arise  from  the 
imidazole  ring,  which  is  a  general  base  and  a  nucleophile.  Thus,  the  imidazole  group  can  cause 
epimerization and may participate in different reactions during the synthesis of asymmetric amino 
acid derivatives [8]. 
There remains a need for a deeper understanding of the conformational properties of many of these 
amino acids as well as for the design, synthesis and conformational analysis of novel amino acids with 
well-defined 
1 and 
2 angles. 
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Figure 11. Some β-methyl-substituted amino acid analogues [87–91]. 
O
OH
CH3
NH2
O
OH
CH3
NH2
O H
O
OH
CH3
NH2
O H
N
H
O
OH
CH3
NH2 N
H
O
OH
CH3
NH2
N
115 116 117
118 119  
The Importance of Histidine Amino Acid as Residue in Bioactive Molecules and in the Synthesis of 
Biologically Active Compounds 
An example of the use of L-histidine in the synthesis of biologically active compounds is reported 
by Gonzales et al. [92]: They prepared the cyclic carbamate analogs of 120–122 as a part of a novel 
series of muscarinic agonists containing the 2-oxazolidinone ring system, and the conformationally 
restricted derivatives 123–125 (Figure 12), the latter synthesized by the Pictet-Spengler reaction.  
Figure 12. (+) Pilocarpine analogs [92]. 
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It  is  of  interest  that  no  rigid  analog  of  (+) -pilocarpine  has  been  reported  to  have  more  than 
approximately 1% of the agonist activity of the naturally occurring alkaloid. 
Tourwè  et al. [93] replaced the histidine residue in angiotensin IV by various conformationally 
constrained amino acids (Figure 13). 
The substitution of the His
4-Pro
5 dipeptide sequence by the constrained Trp analogue Aia-Gly,  
in  combination  with  β
2hVal  substitution  at  the  N-terminus,  provided  a  new  stable  analogue  
H-(R)-β
2hVal-Tyr-Ile-Aia-Gly-Phe-OH (AL-40) that is a potent ligand for the Ang IV receptor IRAP 
and selective versus AP-N and the AT1 receptor. 
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Figure 13. Conformationally constrained aromatic residues used as His replacements in 
Ang IV [93]. 
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